Brian Keegan
Dermatology · East Windsor, NJNPI 1053516351
Payments from drug & device makers
Across 1,561 payments — averaging $1097.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$407K
- Lilly USA, LLC$351K
- Amgen$299K
- Johnson & Johnson$230K
- Incyte Corporation$113K
- Janssen Scientific Affairs, LLC$111K
- plus $201K from 28 others
What the payments were for
- Consulting fees$20,4461%
- Speaking & faculty fees$1,522,64889%
- Travel & lodging$139,4968%
- Food & beverage$29,2532%
- Education$6100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 291 | $407,039 |
| Lilly USA, LLC | 374 | $351,408 |
| Amgen | 248 | $298,582 |
| Johnson & Johnson(2 entities) | 186 | $230,417 |
| Incyte Corporation | 108 | $113,157 |
| Janssen Scientific Affairs, LLC | 81 | $110,780 |
| Novartis | 58 | $59,489 |
| E.r. Squibb & Sons, L.L.C. | 40 | $43,690 |
| Regeneron Healthcare Solutions, Inc. | 25 | $22,818 |
| Pfizer | 28 | $21,450 |
| Sanofi | 15 | $18,407 |
| LEO Pharma Inc. | 16 | $13,106 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 25 | $10,167 |
| Galderma Laboratories, L.p. | 10 | $7,044 |
| Bristol Myers Squibb | 7 | $4,152 |
| UCB, Inc. | 15 | $232 |
| Sun Pharmaceutical Industries Inc. | 7 | $99 |
| Mayne Pharma Commercial LLC | 5 | $91 |
| Arcutis Biotherapeutics, Inc. | 4 | $63 |
| DUSA Pharmaceuticals, Inc. | 2 | $37 |
| Merck | 2 | $26 |
| Genentech USA, Inc. | 2 | $26 |
| Boehringer Ingelheim | 1 | $20 |
| Journey Medical Corporation | 1 | $20 |
| Promius Pharma LLC | 1 | $15 |
| Aclaris Therapeutics, Inc. | 1 | $15 |
| EPI Health, LLC | 1 | $15 |
| Taro Pharmaceuticals USA, Inc. | 1 | $14 |
| Almirall LLC | 1 | $14 |
| Dermavant Sciences, Inc. | 1 | $14 |
| Dermira, Inc. | 1 | $14 |
| Biofrontera Inc. | 1 | $13 |
| Prugen, Inc. Pharmaceuticals | 1 | $12 |
| Organon | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,712,453 in reported general payments places this provider in the 95th percentile of 394 dermatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 14 | $292,310 |
| Humira(Cf) PenAdalimumab | 27 | $255,003 |
| TremfyaGuselkumab | 14 | $182,568 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 25 | $180,022 |
| OlumiantBaricitinib | 12 | $31,683 |
| ValtrexValacyclovir Hcl | 13 | $7,247 |
| Pimecrolimus | 22 | $4,441 |
| Clobetasol Propionate | 83 | $3,966 |
| Ivermectin | 11 | $3,710 |
| Triamcinolone Acetonide | 319 | $2,993 |
| Metronidazole | 64 | $2,817 |
| Ketoconazole | 134 | $2,506 |
| Fluorouracil | 42 | $2,392 |
| Fluocinolone Acetonide | 38 | $1,631 |
| Tretinoin | 21 | $1,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $230,417 | $182,56814 claims |
| Lilly USA, LLCOlumiant | $351,408 | $31,68312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 394 dermatology providers in New Jersey.
Other dermatology in East Windsor
- Jerry BagelEast Windsor$15.4M
- David NievesEast Windsor$84K
- Jonathan DosikGlen Rock$8.4M
- Omar NoorSomerset$4.6M
- Linda Cappiello-LindsleyHoboken$2.3M
- Winston MoyDenville$1.8M
- Jeanine DownieMontclair$1.2M
- Adolfo Fernandez ObregonHoboken$1.1M
- Mital Patel CohenFlorham Park$799K
- Ronald BernardinVoorhees$688K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.